Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Proteome Sciences Appoints Director of Personalised Medicine

Published: Wednesday, October 30, 2013
Last Updated: Wednesday, October 30, 2013
Bookmark and Share
Proteome Sciences announces it has appointed Dr Chee Gee See as Director of Personalised Medicine with immediate effect.

Chee Gee is a biomarker and translational medicine expert and was a former Biomarker and Experimental Medicine Leader for 5 years at Roche in multiple therapeutic areas including CNS, cardiovascular, respiratory and inflammation. Most notable was his role as the clinical oncology biomarker leader for the pivotal Phase III ToGA Herceptin trial and the co-development of the HER2 companion diagnostic in gastric cancer.  

Prior to this Chee Gee spent 11 years at Glaxo Smith Kline where he was the European Therapeutic Area Analyst for Genetics Research reporting to Dr Allen Roses. He has specialist expertise in regulatory affairs and value-based drug pricing, reimbursement and market access.  

Chee Gee’s role at Proteome Sciences will be to extend its business development strategy and to strengthen the commercial relationships with pharmaceutical, clinical and academic partners globally. 

Commenting on his appointment Christopher Pearce, CEO of Proteome Sciences, said:
“We are delighted to have Dr See join our team at this important juncture in Proteome Sciences’ development as personalised medicine is bepcoming ever more critical in respect to disease diagnosis and prognosis, drug development and patient management.  Chee Gee’s  skills are perfectly suited to enhance our growing reputation in this crucial field of medicine”.

Dr See added:
“I have been extremely impressed with the outstanding and innovative science that underpins Proteome Sciences’ commercial strategy and its range of powerful platform technologies and solutions. These meet the growing needs of the healthcare industry from diagnostics through to therapeutics and patient care and management in a dynamic and rapidly changing market place. I really look forward to working with the team at Proteome Sciences to extend its leading reputation in the markets it serves and to drive growth and revenue.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Deep Protein Profiling Key
Company has encouraged by two recent reports that emphasise the importance of protein profiling to improve outcomes in cancer treatment.
Wednesday, April 06, 2016
Proteome Sciences Extends its Reach Through Collaboration with MedBiomix Partners
Collaborative network alliance provide advanced data-driven solutions to integrate and make better use of protein expression data.
Wednesday, February 04, 2015
Appointment of Non-Executive Director
Company Board announces the appointment of Mr. Martin Diggle.
Friday, October 17, 2014
Proteome Sciences Signs $2m Contract with Genting TauRx Diagnostic Centre
Contract to develop diagnostic panels to detect Alzheimer’s disease and monitor treatment efficacy.
Tuesday, September 30, 2014
Science and Technology Award for TMT at HUPO World Congress
TMT® chemical tags, distributed through Thermo Scientific, have become the global market leader.
Monday, September 15, 2014
Breakthrough Profiling Technology to Improve Cancer Treatment on a Personalized Basis
New research paper published in the peer reviewed journal PLOS ONE.
Saturday, April 12, 2014
Proteome Sciences Announces £5M Placing
Company conditionally places 17,857,143 new ordinary shares.
Monday, February 24, 2014
Proteome Sciences to Develop Cancer Pathway Profiling Assays
New MS3 TMT® mass spectrometry technique to determine relative quantitation of proteins in multiple samples simultaneously.
Monday, June 17, 2013
In-vivo Study Shows CK1D Inhibitors Improve Cognition in Alzheimer’s Model
Proteome Sciences study shows improved cognition using its compounds.
Thursday, January 03, 2013
Stroke Blood Test That Could Increase Use of Most Effective Treatment Five-Fold
UNIGE in collaboration with Proteome Sciences describe a simple blood test.
Friday, September 21, 2012
CK1D Development Update
Proteome Sciences has achieved further milestones in the development of inhibitors of the casein kinase 1 delta (CK1d) target in its Alzheimer's disease portfolio.
Tuesday, August 07, 2012
Stroke Biomarker License to Randox
Stroke biomarker to develop and produce diagnostic tests that could increase by fivefold the number of patients treated for stroke.
Friday, April 06, 2012
Completion of Alzheimer’s Plasma Biomarker Study
The preliminary results demonstrate significant diagnostic and prognostic utilities.
Wednesday, April 04, 2012
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!